-
1
-
-
84855172814
-
The pathogenesis of rheumatoid arthritis
-
10.1056/NEJMra1004965, 22150039
-
McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011, 365:2205-2219. 10.1056/NEJMra1004965, 22150039.
-
(2011)
N Engl J Med
, vol.365
, pp. 2205-2219
-
-
McInnes, I.B.1
Schett, G.2
-
2
-
-
84859862757
-
Updated recommendations for the treatment of rheumatoid arthritis: another step on a long road
-
Daikh DI, St Clair EW. Updated recommendations for the treatment of rheumatoid arthritis: another step on a long road. Arthritis Care Res 2012, 64:648-651.
-
(2012)
Arthritis Care Res
, vol.64
, pp. 648-651
-
-
Daikh, D.I.1
St Clair, E.W.2
-
3
-
-
84859832981
-
2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
-
10.1002/acr.21641, 22473917
-
Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O'Dell J, Winthrop KL, Beukelman T, Bridges SL, Chatham WW, Paulus HE, Suarez-Almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkmann ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012, 64:625-639. 10.1002/acr.21641, 22473917.
-
(2012)
Arthritis Care Res (Hoboken)
, vol.64
, pp. 625-639
-
-
Singh, J.A.1
Furst, D.E.2
Bharat, A.3
Curtis, J.R.4
Kavanaugh, A.F.5
Kremer, J.M.6
Moreland, L.W.7
O'Dell, J.8
Winthrop, K.L.9
Beukelman, T.10
Bridges, S.L.11
Chatham, W.W.12
Paulus, H.E.13
Suarez-Almazor, M.14
Bombardier, C.15
Dougados, M.16
Khanna, D.17
King, C.M.18
Leong, A.L.19
Matteson, E.L.20
Schousboe, J.T.21
Moynihan, E.22
Kolba, K.S.23
Jain, A.24
Volkmann, E.R.25
Agrawal, H.26
Bae, S.27
Mudano, A.S.28
Patkar, N.M.29
Saag, K.G.30
more..
-
4
-
-
80053600391
-
Recent advances in the IL-17 cytokine family
-
10.1016/j.coi.2011.07.006, 3190066, 21852080
-
Gaffen SL. Recent advances in the IL-17 cytokine family. Curr Opin Immunol 2011, 23:613-619. 10.1016/j.coi.2011.07.006, 3190066, 21852080.
-
(2011)
Curr Opin Immunol
, vol.23
, pp. 613-619
-
-
Gaffen, S.L.1
-
5
-
-
69349093225
-
Interleukin-17 and type 17 helper T cells
-
10.1056/NEJMra0707449, 19710487
-
Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009, 361:888-898. 10.1056/NEJMra0707449, 19710487.
-
(2009)
N Engl J Med
, vol.361
, pp. 888-898
-
-
Miossec, P.1
Korn, T.2
Kuchroo, V.K.3
-
6
-
-
84866934694
-
Targeting IL-17 and TH17 cells in chronic inflammation
-
10.1038/nrd3794, 23023676
-
Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov 2012, 11:763-776. 10.1038/nrd3794, 23023676.
-
(2012)
Nat Rev Drug Discov
, vol.11
, pp. 763-776
-
-
Miossec, P.1
Kolls, J.K.2
-
7
-
-
84859017988
-
Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis
-
10.1056/NEJMoa1109017, 22455412
-
Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, Aras G, Li J, Russell CB, Thompson EH, Baumgartner S. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012, 366:1181-1189. 10.1056/NEJMoa1109017, 22455412.
-
(2012)
N Engl J Med
, vol.366
, pp. 1181-1189
-
-
Papp, K.A.1
Leonardi, C.2
Menter, A.3
Ortonne, J.P.4
Krueger, J.G.5
Kricorian, G.6
Aras, G.7
Li, J.8
Russell, C.B.9
Thompson, E.H.10
Baumgartner, S.11
-
8
-
-
0033134608
-
IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis
-
10.1172/JCI5703, 408356, 10225978
-
Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, Saito S, Inoue K, Kamatani N, Gillespie MT, Martin TJ, Suda T. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999, 103:1345-1352. 10.1172/JCI5703, 408356, 10225978.
-
(1999)
J Clin Invest
, vol.103
, pp. 1345-1352
-
-
Kotake, S.1
Udagawa, N.2
Takahashi, N.3
Matsuzaki, K.4
Itoh, K.5
Ishiyama, S.6
Saito, S.7
Inoue, K.8
Kamatani, N.9
Gillespie, M.T.10
Martin, T.J.11
Suda, T.12
-
9
-
-
21644479222
-
Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin
-
10.1186/ar1733, 1175027, 15987480
-
Raza K, Falciani F, Curnow SJ, Ross EJ, Lee CY, Akbar AN, Lord JM, Gordon C, Buckley CD, Salmon M. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther 2005, 7:R784-R795. 10.1186/ar1733, 1175027, 15987480.
-
(2005)
Arthritis Res Ther
, vol.7
-
-
Raza, K.1
Falciani, F.2
Curnow, S.J.3
Ross, E.J.4
Lee, C.Y.5
Akbar, A.N.6
Lord, J.M.7
Gordon, C.8
Buckley, C.D.9
Salmon, M.10
-
10
-
-
0034161692
-
High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism
-
Ziolkowska M, Koc A, Luszczykiewicz G, Ksiezopolska-Pietrzak K, Klimczak E, Chwalinska-Sadowska H, Maslinski W. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol 2000, 164:2832-2838.
-
(2000)
J Immunol
, vol.164
, pp. 2832-2838
-
-
Ziolkowska, M.1
Koc, A.2
Luszczykiewicz, G.3
Ksiezopolska-Pietrzak, K.4
Klimczak, E.5
Chwalinska-Sadowska, H.6
Maslinski, W.7
-
11
-
-
40549138745
-
Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers
-
10.1002/art.23291, 2675006, 18311821
-
Nistala K, Moncrieffe H, Newton KR, Varsani H, Hunter P, Wedderburn LR. Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers. Arthritis Rheum 2008, 58:875-887. 10.1002/art.23291, 2675006, 18311821.
-
(2008)
Arthritis Rheum
, vol.58
, pp. 875-887
-
-
Nistala, K.1
Moncrieffe, H.2
Newton, K.R.3
Varsani, H.4
Hunter, P.5
Wedderburn, L.R.6
-
12
-
-
0031802932
-
Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines
-
Chabaud M, Fossiez F, Taupin JL, Miossec P. Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol 1998, 161:409-414.
-
(1998)
J Immunol
, vol.161
, pp. 409-414
-
-
Chabaud, M.1
Fossiez, F.2
Taupin, J.L.3
Miossec, P.4
-
13
-
-
77950535421
-
LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study
-
10.1002/art.27334, 20131262
-
Genovese MC, Van den Bosch F, Roberson SA, Bojin S, Biagini IM, Ryan P, Sloan-Lancaster J. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 2010, 62:929-939. 10.1002/art.27334, 20131262.
-
(2010)
Arthritis Rheum
, vol.62
, pp. 929-939
-
-
Genovese, M.C.1
Van den Bosch, F.2
Roberson, S.A.3
Bojin, S.4
Biagini, I.M.5
Ryan, P.6
Sloan-Lancaster, J.7
-
14
-
-
77958072084
-
Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis
-
10.1126/scitranslmed.3001107, 20926833, Psoriasis Study Group
-
Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, Antoni C, Draelos Z, Gold MH, Durez P, Tak PP, Gomez-Reino JJ, Foster CS, Kim RY, Samson CM, Falk NS, Chu DS, Callanan D, Nguyen QD, Rose K, Haider A, Di Padova F, Psoriasis Study Group Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010, 2:52ra72. 10.1126/scitranslmed.3001107, 20926833, Psoriasis Study Group.
-
(2010)
Sci Transl Med
, vol.2
-
-
Hueber, W.1
Patel, D.D.2
Dryja, T.3
Wright, A.M.4
Koroleva, I.5
Bruin, G.6
Antoni, C.7
Draelos, Z.8
Gold, M.H.9
Durez, P.10
Tak, P.P.11
Gomez-Reino, J.J.12
Foster, C.S.13
Kim, R.Y.14
Samson, C.M.15
Falk, N.S.16
Chu, D.S.17
Callanan, D.18
Nguyen, Q.D.19
Rose, K.20
Haider, A.21
Di Padova, F.22
more..
-
15
-
-
0026629688
-
The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis
-
10.1002/art.1780350502, 1575785
-
Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992, 35:498-502. 10.1002/art.1780350502, 1575785.
-
(1992)
Arthritis Rheum
, vol.35
, pp. 498-502
-
-
Hochberg, M.C.1
Chang, R.W.2
Dwosh, I.3
Lindsey, S.4
Pincus, T.5
Wolfe, F.6
-
16
-
-
84887411348
-
Blood-based biomarkers in a healthy volunteer study of AMG 827 enable assessment of target coverage and functional blockade of the human IL-17 receptor [abstract]
-
Vancouver, BC, Canada
-
Martin D, Kerkof K, Chen G, Rees W, Leshinsky N, Kotzin B, Rand H, Williams G, Stevens E, Russell C. Blood-based biomarkers in a healthy volunteer study of AMG 827 enable assessment of target coverage and functional blockade of the human IL-17 receptor [abstract]. Federation of Clinical Immunology Societies 12th Annual Meeting 2012, Vancouver, BC, Canada.
-
(2012)
Federation of Clinical Immunology Societies 12th Annual Meeting
-
-
Martin, D.1
Kerkof, K.2
Chen, G.3
Rees, W.4
Leshinsky, N.5
Kotzin, B.6
Rand, H.7
Williams, G.8
Stevens, E.9
Russell, C.10
-
17
-
-
84868680312
-
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
-
10.1136/gutjnl-2011-301668, 22595313, Secukinumab in Crohn's Disease Study Group
-
Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, Wehkamp J, Feagan BG, Yao MD, Karczewski M, Karczewski J, Pezous N, Bek S, Bruin G, Mellgard B, Berger C, Londei M, Bertolino AP, Tougas G, Travis SP, Secukinumab in Crohn's Disease Study Group Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012, 61:1693-1700. 10.1136/gutjnl-2011-301668, 22595313, Secukinumab in Crohn's Disease Study Group.
-
(2012)
Gut
, vol.61
, pp. 1693-1700
-
-
Hueber, W.1
Sands, B.E.2
Lewitzky, S.3
Vandemeulebroecke, M.4
Reinisch, W.5
Higgins, P.D.6
Wehkamp, J.7
Feagan, B.G.8
Yao, M.D.9
Karczewski, M.10
Karczewski, J.11
Pezous, N.12
Bek, S.13
Bruin, G.14
Mellgard, B.15
Berger, C.16
Londei, M.17
Bertolino, A.P.18
Tougas, G.19
Travis, S.P.20
more..
-
18
-
-
84866391313
-
Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial
-
10.1038/jid.2012.163, 22622425
-
Papp KA, Reid C, Foley P, Sinclair R, Salinger DH, Williams G, Dong H, Krueger JG, Russell CB, Martin DA. Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial. J Invest Dermatol 2012, 132:2466-2469. 10.1038/jid.2012.163, 22622425.
-
(2012)
J Invest Dermatol
, vol.132
, pp. 2466-2469
-
-
Papp, K.A.1
Reid, C.2
Foley, P.3
Sinclair, R.4
Salinger, D.H.5
Williams, G.6
Dong, H.7
Krueger, J.G.8
Russell, C.B.9
Martin, D.A.10
-
19
-
-
84887412452
-
A randomized, double-blind, placebo-controlled, multiple-dose study to evaluate the safety, tolerability, and efficacy of brodalumab (AMG 827) in subjects with rheumatoid arthritis and an inadequate response to methotrexate [abstract 831]
-
doi:10.1002/art.38564
-
Pavelka K, Chon Y, Newmark R, Erondu N, Lin SL. A randomized, double-blind, placebo-controlled, multiple-dose study to evaluate the safety, tolerability, and efficacy of brodalumab (AMG 827) in subjects with rheumatoid arthritis and an inadequate response to methotrexate [abstract 831]. Arthritis Rheum 2012, 64:S362. doi:10.1002/art.38564.
-
(2012)
Arthritis Rheum
, vol.64
-
-
Pavelka, K.1
Chon, Y.2
Newmark, R.3
Erondu, N.4
Lin, S.L.5
-
20
-
-
84874552498
-
A phase 2 study of multiple subcutaneous doses of LY2439821, an anti-IL-17 monoclonal antibody, in patients with rheumatoid arthritis in two populations: naive to biologic therapy or inadequate responders to tumor necrosis factor α inhibitors [abstract]
-
Genovese MC, Greenwald MW, Cho CS, Berman A, Jin L, Cameron G, Wang L, Xie L, Braun D, Subhashis B, Warner L. A phase 2 study of multiple subcutaneous doses of LY2439821, an anti-IL-17 monoclonal antibody, in patients with rheumatoid arthritis in two populations: naive to biologic therapy or inadequate responders to tumor necrosis factor α inhibitors [abstract]. Arthritis Rheum 2011, 63:2591.
-
(2011)
Arthritis Rheum
, vol.63
, pp. 2591
-
-
Genovese, M.C.1
Greenwald, M.W.2
Cho, C.S.3
Berman, A.4
Jin, L.5
Cameron, G.6
Wang, L.7
Xie, L.8
Braun, D.9
Subhashis, B.10
Warner, L.11
-
21
-
-
84877603562
-
Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study
-
10.1136/annrheumdis-2012-201601, 22730366
-
Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Mazurov V, Aelion JA, Lee SH, Codding CE, Kellner H, Ikawa T, Hugot S, Mpofu S. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis 2013, 72:863-869. 10.1136/annrheumdis-2012-201601, 22730366.
-
(2013)
Ann Rheum Dis
, vol.72
, pp. 863-869
-
-
Genovese, M.C.1
Durez, P.2
Richards, H.B.3
Supronik, J.4
Dokoupilova, E.5
Mazurov, V.6
Aelion, J.A.7
Lee, S.H.8
Codding, C.E.9
Kellner, H.10
Ikawa, T.11
Hugot, S.12
Mpofu, S.13
|